MDT

89.64

-0.03%↓

VEEV

281.99

+1.94%↑

A

113.98

-2.16%↓

WBA

11.48

-0.26%↓

HQY

97.59

-2.48%↓

MDT

89.64

-0.03%↓

VEEV

281.99

+1.94%↑

A

113.98

-2.16%↓

WBA

11.48

-0.26%↓

HQY

97.59

-2.48%↓

MDT

89.64

-0.03%↓

VEEV

281.99

+1.94%↑

A

113.98

-2.16%↓

WBA

11.48

-0.26%↓

HQY

97.59

-2.48%↓

MDT

89.64

-0.03%↓

VEEV

281.99

+1.94%↑

A

113.98

-2.16%↓

WBA

11.48

-0.26%↓

HQY

97.59

-2.48%↓

MDT

89.64

-0.03%↓

VEEV

281.99

+1.94%↑

A

113.98

-2.16%↓

WBA

11.48

-0.26%↓

HQY

97.59

-2.48%↓

Search

Coherus Biosciences Inc

Затворен

СекторЗдравеопазване

0.88 -2.22

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

0.87

Максимум

0.92

Ключови измерители

By Trading Economics

Приходи

-5.9M

-57M

Продажби

-47M

7.6M

P/E

Средно за сектора

2.158

39.857

Марж на печалбата

-744.427

Служители

221

EBITDA

115K

-44M

Препоръки

By TipRanks

Препоръки

Купи

12-месечна прогноза

+347.78% upside

Дивиденти

By Dow Jones

Следващи печалби

7.08.2025 г.

Пазарни показатели

By TradingEconomics

Пазарна капитализация

-8.1M

110M

Предишно отваряне

3.1

Предишно затваряне

0.88

Настроения в новините

By Acuity

50%

50%

154 / 376 Класиране в Healthcare

Техническа оценка

By Trading Central

Увереност

Weak Bearish Evidence

Coherus Biosciences Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

18.07.2025 г., 21:01 ч. UTC

Печалби

Charles Schwab Profit Jumps on Tariff Trading Surge -- 2nd Update

18.07.2025 г., 20:50 ч. UTC

Пазарно говорене
Печалби

Tech, Media & Telecom Roundup: Market Talk

18.07.2025 г., 20:50 ч. UTC

Пазарно говорене
Печалби

Auto & Transport Roundup: Market Talk

18.07.2025 г., 20:50 ч. UTC

Пазарно говорене
Печалби

Basic Materials Roundup: Market Talk

18.07.2025 г., 20:46 ч. UTC

Печалби

Strong Earnings Fuel Stock-Market Records This Week -- WSJ

18.07.2025 г., 20:39 ч. UTC

Придобивния, сливания и поглъщания

Union Pacific Considering a Norfolk Southern Buyout, Report Says. Here's What Will Matter. -- Barrons.com

18.07.2025 г., 20:36 ч. UTC

Печалби

3M Gives Investors a 'Beat and Raise.' The Stock Is Rising. -- Barrons.com

18.07.2025 г., 20:16 ч. UTC

Придобивния, сливания и поглъщания

Chevron-Hess Deal Close Is Good News for Wall Street's Takeover Arbitragers -- Barrons.com

18.07.2025 г., 20:15 ч. UTC

Пазарно говорене

Global Commodities Roundup: Market Talk

18.07.2025 г., 20:02 ч. UTC

Пазарно говорене

Gold Higher to Close Out Week -- Market Talk

18.07.2025 г., 19:14 ч. UTC

Пазарно говорене

U.S. Natural Gas Futures Post Weekly Gains -- Market Talk

18.07.2025 г., 19:06 ч. UTC

Пазарно говорене

Oil Futures Snap Two-Week Winning Streak -- Market Talk

18.07.2025 г., 18:24 ч. UTC

Печалби

These Stocks Are Moving the Most Today: Netflix, Sarepta, Amex, Norfolk Southern, Interactive Brokers, Talen, Schwab, and More -- Barrons.com

18.07.2025 г., 18:19 ч. UTC

Печалби

American Express Shares Drop as Earnings Beat, Record Revenue Fail to Impress -- Barrons.com

18.07.2025 г., 18:11 ч. UTC

Придобивния, сливания и поглъщания

Oil CEOs Get Their Revenge on Biden's Antitrust Enforcers -- WSJ

18.07.2025 г., 18:11 ч. UTC

Печалби

Netflix Earnings Show That YouTube Is the Streamer to Fear -- Barrons.com

18.07.2025 г., 17:35 ч. UTC

Пазарно говорене

U.S. Oil Rig Count Falls by 2 to 422 -- Market Talk

18.07.2025 г., 16:29 ч. UTC

Пазарно говорене

Crude Rally on EU's Russia Sanctions Peters Out -- Market Talk

18.07.2025 г., 16:28 ч. UTC

Придобивния, сливания и поглъщания

Union Pacific Considering a Norfolk Southern Buyout, Report Says. Here's What Will Matter. -- Barrons.com

18.07.2025 г., 16:22 ч. UTC

Печалби

These Stocks Are Moving the Most Today: Netflix, Amex, Norfolk Southern, Interactive Brokers, Talen, Schwab, Sarepta, and More -- Barrons.com

18.07.2025 г., 16:20 ч. UTC

Пазарно говорене
Печалби

Financial Services Roundup: Market Talk

18.07.2025 г., 16:20 ч. UTC

Пазарно говорене
Печалби

Tech, Media & Telecom Roundup: Market Talk

18.07.2025 г., 16:20 ч. UTC

Пазарно говорене
Печалби

Auto & Transport Roundup: Market Talk

18.07.2025 г., 16:20 ч. UTC

Пазарно говорене
Придобивния, сливания и поглъщания

Energy & Utilities Roundup: Market Talk

18.07.2025 г., 16:20 ч. UTC

Пазарно говорене
Печалби

Basic Materials Roundup: Market Talk

18.07.2025 г., 16:15 ч. UTC

Пазарно говорене

Global Commodities Roundup: Market Talk

18.07.2025 г., 16:04 ч. UTC

Печалби

Charles Schwab Profit Jumps on Tariff Trading Surge -- Update

18.07.2025 г., 15:58 ч. UTC

Пазарно говорене

Global Equities Roundup: Market Talk

18.07.2025 г., 15:58 ч. UTC

Пазарно говорене

Aluminum Gains on U.S. Dollar Weakness, Scrap Imports -- Market Talk

18.07.2025 г., 15:47 ч. UTC

Пазарно говорене
Печалби

Netflix Shifting Focus to Engagement with New Content -- Market Talk

Сравнение с други в отрасъла

Ценова промяна

Coherus Biosciences Inc Прогноза

Ценова цел

By TipRanks

347.78% нагоре

12-месечна прогноза

Среден 4.03 USD  347.78%

Висок 7 USD

Нисък 1.05 USD

Според 5 анализатори от Wall Street, предложили 12-месечна ценова цел за Coherus Biosciences Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Купи

5 ratings

3

Купи

2

Задържане

0

Продай

Техническа оценка

By Trading Central

0.9209 / 1.05Подкрепа & съпротива

Краткосрочен план

Weak Bearish Evidence

Средносрочен план

Weak Bullish Evidence

Дългосрочен план

Weak Bearish Evidence

Настроение

By Acuity

154 / 376 Класиране в Здравеопазване

Настроения в новините

Neutral

Волатилност

Под средното

Обем новини (RCV)

Под средното

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

$

Относно Coherus Biosciences Inc

Coherus BioSciences, Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of cancer treatments primarily in the United States. The company develops UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor; LOQTORZI, a novel PD-1 inhibitor; and Casdozokitug, an investigational recombinant human immunoglobulin isotype G1 (IgG1) monoclonal antibody targeting interleukin 27. It is also developing CHS-114, an investigational highly specific human afucosylated IgG1 monoclonal antibody selectively targeting CCR8, a chemokine receptor highly expressed on Treg cells in the tumor microenvironment (TME); and CHS-1000, an antibody targeting human ILT4 designed to improve anti-PD-1 clinical benefit by transforming an unfavorable TME to a more favorable TME. In addition, the company's licensed immuno-oncology programs include NZV930, an antibody designed to inhibit cluster of differentiation 73; and GSK4381562, an antibody targeting CD112R for the treatment of solid tumors. Further, it offers YUSIMRY, a biosimilar to Humira for the treatment of patients with inflammatory diseases characterized by increased production of tumor necrosis factor (TNF) in the body, including rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, psoriasis, and ulcerative colitis. It collaboration agreement with Junshi Biosciences for the co-development and commercialization of toripalimab; agreement with Surface and Adimab LLC; license agreements with Bioeq AG and Genentech, Inc., as well as Vaccinex, Inc.; and out-licensing agreement with Novartis Institutes for Biomedical Research, Inc. and GlaxoSmithKline Intellectual Property No. 4 Limited. The company was formerly known as BioGenerics, Inc. and changed its name to Coherus BioSciences, Inc. in April 2012. Coherus BioSciences, Inc. was incorporated in 2010 and is headquartered in Redwood City, California.